Jack Heath, et al. Genome Editing of BG1/2Promoter Leads to Robust HbF Induction In Vivo, While Editing of BCL11A Erythroid Enhancer Results in Erythroid Defects. Presented at the 24th Congress of the European Hematology Association (EHA), June 13 – 16, 2019.